MX2021013631A - Anticuerpos anti-cd40 para el uso en el tratamiento de t1dm e insulitis. - Google Patents

Anticuerpos anti-cd40 para el uso en el tratamiento de t1dm e insulitis.

Info

Publication number
MX2021013631A
MX2021013631A MX2021013631A MX2021013631A MX2021013631A MX 2021013631 A MX2021013631 A MX 2021013631A MX 2021013631 A MX2021013631 A MX 2021013631A MX 2021013631 A MX2021013631 A MX 2021013631A MX 2021013631 A MX2021013631 A MX 2021013631A
Authority
MX
Mexico
Prior art keywords
antibodies
t1dm
treatment
insulitis
therapies
Prior art date
Application number
MX2021013631A
Other languages
English (en)
Inventor
Pascal Espie
James Rush
Allison Goldfine
Rainer Mussmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2021013631A publication Critical patent/MX2021013631A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La divulgación se refiere a métodos, regímenes de tratamiento, usos, equipos y terapias para el tratamiento de T1DM, empleando anticuerpos anti-CD40.
MX2021013631A 2019-05-08 2020-05-06 Anticuerpos anti-cd40 para el uso en el tratamiento de t1dm e insulitis. MX2021013631A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962844960P 2019-05-08 2019-05-08
PCT/IB2020/054271 WO2020225736A1 (en) 2019-05-08 2020-05-06 Anti-cd40 antibodies for use in treatment of t1dm and insulitis

Publications (1)

Publication Number Publication Date
MX2021013631A true MX2021013631A (es) 2022-04-12

Family

ID=70680549

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013631A MX2021013631A (es) 2019-05-08 2020-05-06 Anticuerpos anti-cd40 para el uso en el tratamiento de t1dm e insulitis.

Country Status (13)

Country Link
US (1) US20220195061A1 (es)
EP (1) EP3966240A1 (es)
JP (2) JP2021518854A (es)
KR (1) KR20220007086A (es)
CN (1) CN113784985A (es)
AU (1) AU2020267953A1 (es)
BR (1) BR112021021923A2 (es)
CA (1) CA3137682A1 (es)
CL (1) CL2021002889A1 (es)
IL (1) IL287464A (es)
MX (1) MX2021013631A (es)
TW (1) TW202108617A (es)
WO (1) WO2020225736A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
PT1707627E (pt) 2003-12-25 2013-01-24 Kyowa Hakko Kirin Co Ltd Mutante antagonista de anticorpo anti-cd40
PL1889065T3 (pl) * 2005-05-18 2013-12-31 Novartis Ag Metody diagnostyki i leczenia chorób posiadających składnik autoimmunologiczny i/lub zapalny
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
SI3178851T1 (sl) 2010-03-31 2020-09-30 Boehringer Inhelheim International Gmbh Anti-CD40 protitelesa
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
MX2018002708A (es) * 2015-09-04 2018-08-01 Primatope Therapeutics Inc Anticuerpos anti-cd40 humanizados y usos de los mismos.
CA3094600A1 (en) * 2018-04-13 2019-10-17 Novartis Ag Anti-cd40 antibodies for use in prevention of graft rejection

Also Published As

Publication number Publication date
AU2020267953A1 (en) 2021-11-18
IL287464A (en) 2021-12-01
TW202108617A (zh) 2021-03-01
JP2021518854A (ja) 2021-08-05
JP2022116272A (ja) 2022-08-09
EP3966240A1 (en) 2022-03-16
BR112021021923A2 (pt) 2022-02-22
CN113784985A (zh) 2021-12-10
CL2021002889A1 (es) 2022-08-12
US20220195061A1 (en) 2022-06-23
CA3137682A1 (en) 2020-11-12
KR20220007086A (ko) 2022-01-18
WO2020225736A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2020005463A (es) Anticuerpos anti grupo de diferenciacion 47 (anti-cd47) y sus usos para tratar cancer.
MX2017003565A (es) Anticuerpos anti-edad para el tratamiento de inflamacion y trastornos autoinmunes.
PH12020552229A1 (en) Il-11ra antibodies
PH12020552232A1 (en) IL-11 Antibodies
MX2022015631A (es) Anticuerpos anti-cd40 humanizados y usos de los mismos.
MX2021005887A (es) Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular hemoglobina.
WO2019014328A3 (en) AGONISTIC ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
EA201691748A1 (ru) Антитела анти-cd38 для лечения острого лимфобластного лейкоза
MX361242B (es) Anticuerpos de dominio sencillo contra tnf-alfa y usos de los mismos.
MX2020010269A (es) Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa.
MX2021016049A (es) Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.
PH12020552059A1 (en) Dosing regimen for the treatment of pi3k related disorders
WO2018209022A3 (en) Methods of treating neuropsychiatric disorders
CL2020001123A1 (es) Anticuerpos anti-cd40 para el uso en el tratamiento del síndrome de sjögren.
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
MX2021002754A (es) Tratamiento del autismo y trastornos dentro del espectro del autismo con composiciones de biotina.
MX2022013557A (es) Tratamiento combinado con anticuerpo anti-cd40 contra el cáncer.
MX2020010722A (es) Anticuerpos anti-cd40 para uso en la prevencion del rechazo de injertos.
MX2021008305A (es) Anticuerpos anti-cd40 para el uso en el tratamiento de hidradenitis supurativa.
WO2019075216A8 (en) Plectin-1 binding antibodies and uses thereof
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
MX2021005751A (es) Anticuerpos contra mucina 16 y métodos de uso de los mismos.